PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Ibuprofen Sodium Tension Headache Study
- Conditions
- Pain
- Interventions
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 226
- Registration Number
- NCT01362491
- Locations
- πΊπΈ
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
PK And Safety Study Of PF-04171327 In Healthy Japanese And Western Subjects In Fasting And Fed Conditions
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2011-10-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT01362673
- Locations
- πΊπΈ
Pfizer Investigational Site, Glendale, California, United States
A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth
- Conditions
- Infant Developmental Assessment
- Interventions
- Other: Unintentional exposure in utero
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7
- Registration Number
- NCT01362660
- Locations
- πΊπΈ
Pfizer Investigational Site, Salt Lake City, Utah, United States
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: Active Comparator (erlotinib)Drug: Placebo PF00299804
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 878
- Registration Number
- NCT01360554
- Locations
- πΊπΈ
Westwood Bowyer Clinic, Peter Morton Medical Building, Los Angeles, California, United States
πΊπΈWinship Cancer Institute of Emory University, Atlanta, Georgia, United States
πΊπΈEmory Clinic, Atlanta, Georgia, United States
A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 223
- Registration Number
- NCT01359150
- Locations
- π΅π±
Pfizer Investigational Site, Wroclaw, Poland
A Study To Determine Bioequivalence Between The Commercial Femulen Tablets And A Reformulation Of Femulen Tablets In Healthy Female Subjects
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT01359163
- Locations
- πΈπ¬
Pfizer Investigational Site, Singapore, Singapore
Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction
- Conditions
- Mild Hepatic DysfunctionModerate Hepatic Dysfunction
- Interventions
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT01358565
- Locations
- πΏπ¦
Pfizer Investigational Site, Newton Park, Port Elizabeth, South Africa
Heat Wrap Device Safety With Age and Body Fat
- Conditions
- Back Pain
- Interventions
- Device: thermal therapyDevice: marketed heatwrap
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 57
- Registration Number
- NCT01355653
- Locations
- πΊπΈ
Pfizer Investigational Site, Loma Linda, California, United States
Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
- Conditions
- Vasomotor SymptomsMajor Depressive Disorder
- Interventions
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT01353963
- Locations
- π΅π
Private Clinic, Pasay City, Philippines
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
- Conditions
- Healthy
- Interventions
- Biological: rLP2086Other: Placebo
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3301
- Registration Number
- NCT01352845
- Locations
- πΊπΈ
Coastal Clinical Research, Inc., Mobile, Alabama, United States
πΊπΈClinical Research Advantage, Inc./Desert Clinical Research, LLC, Mesa, Arizona, United States
πΊπΈAnaheim Clinical Trials LLC, Anaheim, California, United States